FINAL RESULTS OF THE NCRI CLL210 TRIAL OF ALEMTUZUMAB, DEXAMETHASONE AND LENALIDOMIDE IN PATIENTS WITH HIGH-RISK CLL (ORIGINAL PROTOCOL)

Collapse authors list.
Pettitt, AR, Polydoros, F, Dodd, J, Oates, M, Lin, K, Kalakonda, N, McCarthy, H, Bloor, A, Schuh, A, Duncombe, A et al (show 6 more authors) , Dearden, C, Fegan, C, Kennedy, B, Yap, C, Coupland, SE ORCID: 0000-0002-1464-2069 and Hillmen, P (2016) FINAL RESULTS OF THE NCRI CLL210 TRIAL OF ALEMTUZUMAB, DEXAMETHASONE AND LENALIDOMIDE IN PATIENTS WITH HIGH-RISK CLL (ORIGINAL PROTOCOL). .

Text CLL210 EHA 2016 Final Version.docx - Submitted version Download (26kB)